BACKGROUND: This prospective randomized-controlled animal study was designed to determine the effects of atorvastatin on experimentally induced endometriosis in a rat model. METHODS: Thirty-seven Wistar-Albino rats in which endometriotic implants were induced were randomly divided into four groups. Group I (Low-dose atorvastatin group, eight rats) were given 0.5 mg kg(-1) day(-1) oral atorvastatin. Group II (High-dose atorvastatin group, 10 rats) were given 2.5 mg kg(-1) day(-1) oral atorvastatin. Group III were given a single dose of 1 mg kg(-1) s.c. leuprolide acetate (GnRH agonist group, nine rats). Group IV were given no medication and served as controls (10 rats). All rats received the treatment for 21 days and were then euthanized to assess the implants' size, vascular endothelial growth factor (VEGF) level in peritoneal fluid and histological score. RESULTS: At the end of the treatment, the mean areas of implants were smaller and VEGF levels in peritoneal fluid were lower in Groups II and III than those in Group I and the control group (all P < 0.05). The mean areas of implants decreased from 41.2 +/- 13.9 to 22.7 +/- 13.9 mm(2) after medication in Group II and decreased from 41.2 +/- 18.1 to 13.1 +/- 13.8 mm(2) in Group III (both P < 0.05), whereas in Group I, the mean area increased from 43.0 +/- 12.7 to 50.5 +/- 13.9 mm(2) (P < 0.05). CONCLUSIONS: High-dose atorvastatin caused a significant regression of endometriotic implants.
BACKGROUND: This prospective randomized-controlled animal study was designed to determine the effects of atorvastatin on experimentally induced endometriosis in a rat model. METHODS: Thirty-seven Wistar-Albino rats in which endometriotic implants were induced were randomly divided into four groups. Group I (Low-dose atorvastatin group, eight rats) were given 0.5 mg kg(-1) day(-1) oral atorvastatin. Group II (High-dose atorvastatin group, 10 rats) were given 2.5 mg kg(-1) day(-1) oral atorvastatin. Group III were given a single dose of 1 mg kg(-1) s.c. leuprolide acetate (GnRH agonist group, nine rats). Group IV were given no medication and served as controls (10 rats). All rats received the treatment for 21 days and were then euthanized to assess the implants' size, vascular endothelial growth factor (VEGF) level in peritoneal fluid and histological score. RESULTS: At the end of the treatment, the mean areas of implants were smaller and VEGF levels in peritoneal fluid were lower in Groups II and III than those in Group I and the control group (all P < 0.05). The mean areas of implants decreased from 41.2 +/- 13.9 to 22.7 +/- 13.9 mm(2) after medication in Group II and decreased from 41.2 +/- 18.1 to 13.1 +/- 13.8 mm(2) in Group III (both P < 0.05), whereas in Group I, the mean area increased from 43.0 +/- 12.7 to 50.5 +/- 13.9 mm(2) (P < 0.05). CONCLUSIONS: High-dose atorvastatin caused a significant regression of endometriotic implants.
Authors: Hugh S Taylor; Myles Alderman Iii; Thomas M D'Hooghe; Asgerally T Fazleabas; Antoni J Duleba Journal: Biol Reprod Date: 2017-07-01 Impact factor: 4.285
Authors: Hakan Cakmak; Murat Basar; Yasemin Seval-Celik; Kevin G Osteen; Antoni J Duleba; Hugh S Taylor; Charles J Lockwood; Aydin Arici Journal: Reprod Sci Date: 2012-01-19 Impact factor: 3.060
Authors: Anna Sokalska; Donna H Wong; Amanda Cress; Piotr C Piotrowski; Izabela Rzepczynska; Jesus Villanueva; Antoni J Duleba Journal: J Clin Endocrinol Metab Date: 2010-04-28 Impact factor: 5.958
Authors: Kaylon L Bruner-Tran; Kevin G Osteen; Hugh S Taylor; Anna Sokalska; Kaitlin Haines; Antoni J Duleba Journal: Biol Reprod Date: 2010-09-15 Impact factor: 4.285
Authors: Anna Sokalska; MariaPia Anderson; Jesus Villanueva; Israel Ortega; Kaylon L Bruner-Tran; Kevin G Osteen; Antoni J Duleba Journal: J Clin Endocrinol Metab Date: 2013-01-21 Impact factor: 5.958